3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
6
Breast
2
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Renal Cell
38
Kidney Neoplasms
20
Melanoma
14
Neoplasm Metastasis
13
Prostatic Neoplasms
6
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Uterine Cervical Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Lymphoma
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Vaginal Neoplasms
1
Turcot syndrome
1
Skin Neoplasms
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Multiple Myeloma
1
Microsatellite Instability
1
Mesothelioma, Malignant
1
Interventions
pembrolizumab
7
Nivolumab
4
Carboplatin
4
Taxes
3
Paclitaxel
3
Gene Expression Profiling
3
rucaparib
2
aflibercept
2
Radiotherapy
2
Polymerase Chain Reaction
2
Leucovorin
2
Irinotecan
2
Interleukin-12 Subunit p35
2
Fluorouracil
2
Drug Therapy
2
Capecitabine
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
veliparib
1
trastuzumab deruxtecan
1
tocilizumab
1
selinexor
1
olaparib
1
liposomal doxorubicin
1
eribulin
1
entinostat
1
dehydroftorafur
1
cc-486
1
cabozantinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Interleukin-2
×
Genitourinary
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled